Eliot Charles, MiroBio executive chairman
Oxford spinout nabs almost $100M in new cash to test PD-1 in autoimmune diseases and hunt for a CEO
After about 15 years in an Oxford lab and three more years in the upstart world following a 2019 spinout, MiroBio is ready to enter …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
